Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Continuous Topotecan in Recurrent Ovarian Cancer
NCT00313612Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2006
- Primary completion
- May 2011
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and topotecan liposome in ovarian epithelial cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Primary endpoints: Overall Clinical Response Rate at 24 weeks and Toxic Effects. Started Jan 2006; status: terminated.
02
Drugs
oxaliplatintopotecan liposome
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00313612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313612.